Understanding the Market | TRANSTHERA-B rises over 15% again, total market value surpasses HKD 40 billion, and the Phase II clinical trial for Engeletinib is approved to proceed

Zhitong
2025.09.11 02:53
portai
I'm PortAI, I can summarize articles.

TRANSTHERA-B rose over 15% again, with a total market value briefly surpassing HKD 40 billion. As of the time of publication, it rose 11.11%, trading at HKD 100, with a transaction volume of HKD 148 million. In terms of news, TRANSTHERA announced that its core product, TT-00420, in combination with Fulvestrant, has received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative or low-expressing (HER2-) recurrent or metastatic breast cancer that has failed previous treatments. The clinical treatment strategy of combining TT-00420 with Fulvestrant may bring new breakthroughs in the treatment of breast cancer patients. In addition, the Shanghai Stock Exchange and Shenzhen Stock Exchange recently announced that TRANSTHERA has been added to the Hong Kong Stock Connect eligible list, effective from September 8. Guoyuan International stated that the company is a leader in R&D within its niche industry, and TT-00420 is the world's first and only FGFR inhibitor to enter the registration clinical stage for the treatment of recurrent or refractory cholangiocarcinoma patients. It is also the world's first investigational drug that may simultaneously inhibit the FGFR/JAK pathway and has clinical efficacy evidence targeting metastatic castration-resistant prostate cancer

According to Zhitong Finance APP, TRANSTHERA-B (02617) has risen over 15% again, with a total market value briefly surpassing HKD 40 billion. As of the time of publication, it has increased by 11.11%, trading at HKD 100, with a transaction volume of HKD 148 million.

In terms of news, TRANSTHERA announced that its core product, TT-00420, in combination with Fulvestrant, has received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative or low-expressing (HER2-) recurrent or metastatic breast cancer that has failed previous treatments. The clinical treatment strategy of TT-00420 combined with Fulvestrant may bring new breakthroughs in the treatment of breast cancer patients.

Additionally, the Shanghai Stock Exchange and Shenzhen Stock Exchange recently announced that TRANSTHERA has been added to the Hong Kong Stock Connect eligible list, effective from September 8. Guoyuan International stated that the company is a leader in research and development in its niche industry, and TT-00420 is the world's first and only FGFR inhibitor to enter the registration clinical stage for the treatment of recurrent or refractory cholangiocarcinoma patients. It is also the world's first research drug that may simultaneously inhibit the FGFR/JAK pathway and has clinical efficacy evidence targeting metastatic castration-resistant prostate cancer

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.